Tropisetron (Hydrochloride)

Tropisetron Hydrochloride (SDZ-ICS-930) is an effective neuroprotective agent that acts as a 5-HT3 receptor antagonist, a calmodulin inhibitor, and an α7-nAChRreceptor agonist, with an IC50 of 70.1 nM for the 5-HT3 receptor. Tropisetron Hydrochloride has anti-inflammatory properties and immune-regulating functions, effectively alleviating symptoms associated with chemotherapy and post-surgery. Tropisetron Hydrochloride reduces Ab (HY-P4867) -induced hippocampal neuroinflammation[1][2][3][4].

Product Specifications

CAS Number

[105826-92-4]

Product Name Alternative

SDZ-ICS-930

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

5-HT Receptor; nAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Tropisetron-Hydrochloride.html

Purity

99.97

Solubility

DMSO : 70 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

Smiles

O=C(C1=CNC2=C1C=CC=C2)O[C@H]3C[C@H]4CC[C@H](N4C)C3.[H]Cl

Molecular Formula

C17H21ClN2O2

Molecular Weight

320.81

Precautions

H315, H319, H320

References & Citations

[1]Rahimian R, et al. Tropisetron attenuates amyloid-beta-induced inflammatory and apoptotic responses in rats. Eur J Clin Invest. 2013 Oct;43 (10) :1039-51.|[2]Swartz MM, et al. Tropisetron as a neuroprotective agent against glutamate-induced excitotoxicity and mechanisms of action. Neuropharmacology. 2013 Oct;73:111-21.|[3]Aminian A, et al. Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis. Neuroscience. 2013 Jun 15;248C:299-306.|[4]Rahimian R, et al. Tropisetron upregulates cannabinoid CB1 receptors in cerebellar granule cells: possible involvement of calcineurin. Brain Res. 2011 Oct 12;1417:1-8.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

Lactoferrin

Citation 01

Cancer Lett. 2024 Aug 1:217150.|Acta Pharmacol Sin. 2024 Sep;45 (9) :1821-1831.|Drug Dev Res. 2024 Nov;85 (7) :e70002.|Int J Neuropsychopharmacol. 2019 Sep 1;22 (9) :574-584.